1189190-67-7
Chemical Structure
(R)-Oxybutynin-d10
Synonym(s): Aroxybutynin-d10
- CAS No.: 1189190-67-7
- Formula:C22H21D10NO3
- Molecular Weight:367.55
InChIKey: XIQVNETUBQGFHX-YKPKOBDESA-N
SMILES: O=C(OCC#CCN(C([2H])([2H])C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])[2H])[C@@](O)(C1CCCCC1)C2=CC=CC=C2
Biological Activity: (R)-Oxybutynin-d10 (Aroxybutynin-d10) is deuterium labeled (R)-Oxybutynin. (R)-Oxybutynin (Aroxybutynin) is the racemic isomer of Oxybutynin and an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antispasmodic, antimuscarinic, and anticholinergic activities and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used to study urinary incontinence caused by neurogenic bladder dysfunction[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Oxybutynin-d10 | (R)-Oxybutynin-d10 (Aroxybutynin-d10) is deuterium labeled (R)-Oxybutynin. (R)-Oxybutynin (Aroxybutynin) is the racemic isomer of Oxybutynin and an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antispasmodic, antimuscarinic, and anticholinergic activities and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used to study urinary incontinence caused by neurogenic bladder dysfunction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Oxybutynin | (R)-Oxybutynin (Aroxybutynin), an enantiomer of Oxybutynin, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin exhibits antispasmodic and anticholinergic activities, and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used in the research of urinary incontinence caused by neurogenic bladder dysfunction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Smith ER, et al. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline. Arzneimittelforschung. 1998 Oct;48(10):1012-8. [Content Brief]
- [3]. Zobrist RH, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001 Jul;18(7):1029-34. [Content Brief]
- [4]. Siddiqui MA, et al. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004;64(8):885-912. [Content Brief]
